siplizumab

(redirected from MEDI-507)

siplizumab

A humanised anti-CD2 monoclonal antibody for treating transplant rejection, GVHD, autoimmune disorders (e.g., psoriasis, rheumatoid arthritis), inflammatory bowel disease and CD2-positive lymphoproliferative disorders.
References in periodicals archive ?
A Phase 1 Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia" (Abstract 2727, presented in a poster session, "Novel and Targeted Therapy of NHL," on Sunday, Dec.
Revamped AlloMune System Development Strategy: The company revised its clinical development strategy for the AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.
BioTransplant says it is targeting the use of the Eligix Cell Separation products as a component of the AlloMune System, which, along with its proprietary monoclonal antibody MEDI-507, is being developed as a complete approach to increase the safety and efficacy of immune modulation and transplantation for cancer and other life threatening diseases.
We plan to immediately initiate discussions with potential partners to create new opportunities for the Eligix HDM Cell Separation Systems while also pursuing our primary strategic objective - namely, preserving and maximizing the value of MEDI-507 for our shareholders," stated Donald B.
Food and Drug Administration (FDA) for its MEDI-507 antibody, when used as one of the key components of the AlloMune transplantation system.
The Company also announced a restructuring plan intended to preserve its rights to MEDI-507 while reducing its cash burn rate.
BioTransplant Incorporated (Nasdaq: BTRN) today announced encouraging preliminary results from the partial analysis of data from three Phase II clinical trials for MEDI-507, the Company's humanized monoclonal antibody being tested for the treatment of psoriasis.
Waldmann of the National Cancer Institute found that treatment with MEDI-507 led to long term survival in a well-known murine model of adult T-cell leukemia.
the Company's partner in the development of MEDI-507, has provided an update on its development program for psoriasis.
This restructuring arrangement will not impact the Company's agreement with MedImmune or MedImmune's development efforts for MEDI-507.
In particular, the Company announced that it has reached a settlement agreement with the Catholic University of Louvain preserving BioTransplant's exclusive license to MEDI-507 and implemented several measures intended to further reduce the Company's operating expenses.
BioTransplant is also targeting the use of the Eligix Cell Separation Systems as a component of the AlloMune(TM) System, which, along with its proprietary monoclonal antibody MEDI-507, is being developed as a complete approach to increase the safety and efficacy of immune modulation and transplantation for cancer and other life threatening diseases.